#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	15428	16S	1529	1529	99.8	16S.l6.c30.ctg.1	2003	764.4	0	.	n	.	0	A69G	SNP	69	69	A	286	286	G	816	G,A	539,224	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	15428	16S	1529	1529	99.8	16S.l6.c30.ctg.1	2003	764.4	0	.	n	.	0	C450T	SNP	450	450	C	667	667	T	907	T,C,G	583,244,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	15428	16S	1529	1529	99.8	16S.l6.c30.ctg.1	2003	764.4	0	.	n	.	0	C1450T	SNP	1450	1450	C	1667	1667	T	857	T	788	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	15428	16S	1529	1529	99.8	16S.l6.c30.ctg.1	2003	764.4	1	SNP	n	C1184T	0	.	.	1184	1184	C	1401	1401	C	939	C,A,T	868,1,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	15428	16S	1529	1529	99.8	16S.l6.c30.ctg.1	2003	764.4	0	HET	.	.	.	G1207A	.	1207	1207	G	1424	1424	G	892	G,A	595,235	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	27598	23S	2890	2890	99.93	23S.l6.c4.ctg.1	3454	795.5	0	.	n	.	0	G1337A	SNP	1337	1337	G	1581	1581	A	938	A,G	879,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	27598	23S	2890	2890	99.93	23S.l6.c4.ctg.1	3454	795.5	0	.	n	.	0	T1971C	SNP	1971	1971	T	2215	2215	C	932	C,G	854,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	27598	23S	2890	2890	99.93	23S.l6.c4.ctg.1	3454	795.5	1	SNP	n	A2045G	0	.	.	2045	2045	A	2289	2289	A	892	A	835	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	27598	23S	2890	2890	99.93	23S.l6.c4.ctg.1	3454	795.5	1	SNP	n	C2597T	0	.	.	2597	2597	C	2841	2841	C	832	C	781	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_N_01367c	folP.WHO_N_01367c	1	1	539	2156	folP	852	852	99.88	folP.l15.c30.ctg.1	1532	139.9	0	.	p	.	0	E151K	NONSYN	451	453	GAA	698	700	AAA	202;201;201	A,G,C;A;A	180,1,1;182;179	.	.
folP.WHO_N_01367c	folP.WHO_N_01367c	1	1	539	2156	folP	852	852	99.88	folP.l15.c30.ctg.1	1532	139.9	1	SNP	p	R228S	1	.	.	682	684	AGC	929	931	AGC	263;261;263	A;G;C	241;238;240	folP.WHO_N_01367c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5066	gyrA	2751	2751	100.0	gyrA.l15.c17.ctg.1	3415	148.0	1	SNP	p	S91F	0	.	.	271	273	TCC	605	607	TCC	183;183;182	T;C;C,T	171;169;168,1	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5066	gyrA	2751	2751	100.0	gyrA.l15.c17.ctg.1	3415	148.0	1	SNP	p	D95N	0	.	.	283	285	GAC	617	619	GAC	184;183;184	G;A;C	168;169;171	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5066	gyrA	2751	2751	100.0	gyrA.l15.c17.ctg.1	3415	148.0	1	SNP	p	D95G	0	.	.	283	285	GAC	617	619	GAC	184;183;184	G;A;C	168;169;171	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	27	1730	mtrR	633	633	100.0	mtrR.l15.c17.ctg.1	1387	124.5	1	SNP	p	G45D	0	.	.	133	135	GGC	482	484	GGC	215;215;216	G;G;C	201;199;199	mtrR.WHO_Y_01506:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	852	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c17.ctg.1	974	86.9	0	.	n	.	0	A197.	DEL	197	197	A	581	581	A	203	A,C	187,1	.	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	5140	parC	2304	2304	99.78	parC.l15.c17.ctg.1	2719	187.9	0	.	p	.	0	V435A	NONSYN	1303	1305	GTG	1505	1507	GCA	231;231;234	G;C;A	214;211;211	.	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	5140	parC	2304	2304	99.78	parC.l15.c17.ctg.1	2719	187.9	1	SNP	p	D86N	0	.	.	256	258	GAC	458	460	GAC	224;221;221	G;A;C	209;204;205	parC.WHO_F_01444:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	5140	parC	2304	2304	99.78	parC.l15.c17.ctg.1	2719	187.9	1	SNP	p	S87I	0	.	.	259	261	AGT	461	463	AGT	223;223;223	A;G;T	204;206;208	parC.WHO_F_01444:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	5140	parC	2304	2304	99.78	parC.l15.c17.ctg.1	2719	187.9	1	SNP	p	S87R	0	.	.	259	261	AGT	461	463	AGT	223;223;223	A;G;T	204;206;208	parC.WHO_F_01444:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	5140	parC	2304	2304	99.78	parC.l15.c17.ctg.1	2719	187.9	1	SNP	p	S87W	0	.	.	259	261	AGT	461	463	AGT	223;223;223	A;G;T	204;206;208	parC.WHO_F_01444:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	5140	parC	2304	2304	99.78	parC.l15.c17.ctg.1	2719	187.9	1	SNP	p	S88P	0	.	.	262	264	TCC	464	466	TCC	225;225;227	T;C,T;C	212;211,1;213	parC.WHO_F_01444:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4800	parE	1986	1986	100.0	parE.l15.c4.ctg.1	2539	188.2	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1479	1481	GGC	241;239;242	G;G;C	213;210;209	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.43.002	penA.43.002	1	1	539	4308	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2393	179.1	0	.	p	.	0	P552L	NONSYN	1654	1656	CCG	1934	1936	CTG	182;182;188	C,G;T;G	133,5;125;139	.	.
penA.43.002	penA.43.002	1	1	539	4308	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2393	179.1	1	SNP	p	A311V	0	.	.	931	933	GCA	1211	1213	GCA	230;229;231	G;C;A	220;216;221	penA.43.002:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.43.002	penA.43.002	1	1	539	4308	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2393	179.1	1	SNP	p	I312M	0	.	.	934	936	ATC	1214	1216	ATC	232;229;232	A;T;C	222;219;222	penA.43.002:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.43.002	penA.43.002	1	1	539	4308	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2393	179.1	1	SNP	p	V316P	0	.	.	946	948	GTG	1226	1228	GTG	237;236;239	G;T;G	227;225;228	penA.43.002:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.43.002	penA.43.002	1	1	539	4308	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2393	179.1	1	SNP	p	V316T	0	.	.	946	948	GTG	1226	1228	GTG	237;236;239	G;T;G	227;225;228	penA.43.002:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.43.002	penA.43.002	1	1	539	4308	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2393	179.1	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1730	1732	ACC	228;228;231	A;C;C	202;203;205	penA.43.002:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.43.002	penA.43.002	1	1	539	4308	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2393	179.1	1	SNP	p	V502P	0	.	.	1504	1506	GTG	1784	1786	GTG	213;211;212	G;T,G;G	186;172,2;194	penA.43.002:1:1:V502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.43.002	penA.43.002	1	1	539	4308	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2393	179.1	1	SNP	p	A502V	1	.	.	1504	1506	GTG	1784	1786	GTG	213;211;212	G;T,G;G	186;172,2;194	penA.43.002:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.43.002	penA.43.002	1	1	539	4308	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2393	179.1	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1907	1909	GGC	184;182;182	G;G;C	172;169;171	penA.43.002:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.43.002	penA.43.002	1	1	539	4308	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2393	179.1	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1916	1918	GGC	181;179;177	G;G;C,A	167;165;163,1	penA.43.002:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5924	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	2977	198.1	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1512	1514	CCG	225;229;227	C;C;G	204;209;206	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2180	porA	1146	1146	99.65	porA.l6.c4.ctg.1	1776	122.2	0	.	p	.	0	M83fs	FSHIFT	247	247	A	534	534	C	173	C	163	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3216	porB1b	1047	1047	98.57	porB1b.l15.c17.ctg.1	1415	225.8	0	.	p	.	0	T18M	NONSYN	52	54	ACG	279	281	ATG	275;276;279	A;T;G	249;248;249	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3216	porB1b	1047	1047	98.57	porB1b.l15.c17.ctg.1	1415	225.8	0	.	p	.	0	K143Q	NONSYN	427	429	AAA	654	656	CAA	299;303;306	C;A;A	276;276;277	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3216	porB1b	1047	1047	98.57	porB1b.l15.c17.ctg.1	1415	225.8	0	.	p	.	0	E212D	NONSYN	634	636	GAA	861	863	GAT	268;268;269	G;A;T	251;250;251	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3216	porB1b	1047	1047	98.57	porB1b.l15.c17.ctg.1	1415	225.8	0	.	p	.	0	H213G	NONSYN	637	639	CAT	864	866	GGT	273;271;272	G;G;T	253;253;247	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3216	porB1b	1047	1047	98.57	porB1b.l15.c17.ctg.1	1415	225.8	0	.	p	.	0	V215A	NONSYN	643	645	GTT	870	872	GCT	279;281;280	G;C;T	257;261;261	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3216	porB1b	1047	1047	98.57	porB1b.l15.c17.ctg.1	1415	225.8	0	.	p	.	0	S220T	NONSYN	658	660	AGC	885	887	ACT	282;283;285	A;C;T	258;260;264	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3216	porB1b	1047	1047	98.57	porB1b.l15.c17.ctg.1	1415	225.8	0	.	p	.	0	R257M	NONSYN	769	771	AGG	996	998	ATG	276;274;273	A;T;G	253;254;250	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3216	porB1b	1047	1047	98.57	porB1b.l15.c17.ctg.1	1415	225.8	0	.	p	.	0	R258S	NONSYN	772	774	AGG	999	1001	AGC	274;271;268	A;G;C,T	249;247;242,1	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3216	porB1b	1047	1047	98.57	porB1b.l15.c17.ctg.1	1415	225.8	0	.	p	.	0	A259G	NONSYN	775	777	GCT	1002	1004	GGT	272;273;272	G;G,C,A;T	250;249,2,1;251	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3216	porB1b	1047	1047	98.57	porB1b.l15.c17.ctg.1	1415	225.8	0	.	p	.	0	D297N	NONSYN	889	891	GAC	1116	1118	AAC	271;267;270	A;A,T;C	252;248,1;249	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3216	porB1b	1047	1047	98.57	porB1b.l15.c17.ctg.1	1415	225.8	1	SNP	p	G120K	0	.	.	358	360	GGC	585	587	GGC	257;256;255	G,A;G,A;C,T	240,1;240,1;237,1	porB1b.WHO_P_02204c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	11846	rpoB	4179	4179	100.0	rpoB.l15.c17.ctg.1	4742	249.0	1	SNP	p	H553N	0	.	.	1657	1659	CAT	1956	1958	CAT	234;238;236	C;A;T	224;227;227	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1316	rpsJ	312	312	100.0	rpsJ.l6.c17.ctg.1	1082	120.8	1	SNP	p	V57M	1	.	.	169	171	ATG	584	586	ATG	302;306;306	A;T;G	278;281;281	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
